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Abstract: Our understanding of the etiology, pathogenesis and consequences of acute 
exacerbations of chronic obstructive pulmonary disease (COPD) has increased substantially in 
the last decade. Several new lines of evidence demonstrate that bacterial isolation from sputum 
during acute exacerbation in many instances reﬂ  ects a cause-effect relationship. Placebo-controlled 
antibiotic trials in exacerbations of COPD demonstrate signiﬁ  cant clinical beneﬁ  ts of antibiotic 
treatment in moderate and severe episodes. However, in the multitude of antibiotic comparison 
trials, the choice of antibiotics does not appear to affect the clinical outcome, which can be 
explained by several methodological limitations of these trials. Recently, comparison trials with 
nontraditional end-points have shown differences among antibiotics in the treatment of exacerba-
tions of COPD. Observational studies that have examined clinical outcome of exacerbations have 
repeatedly demonstrated certain clinical characteristics to be associated with treatment failure or 
early relapse. Optimal antibiotic selection for exacerbations has therefore incorporated quantifying 
the risk for a poor outcome of the exacerbation and choosing antibiotics differently for low risk 
and high risk patients, reserving the broader spectrum drugs for the high risk patients. Though 
improved outcomes in exacerbations with antibiotic choice based on such risk stratiﬁ  cation has not 
yet been demonstrated in prospective controlled trials, this approach takes into account concerns 
of disease heterogeneity, antibiotic resistance and judicious antibiotic use in exacerbations.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death 
in the United States and the 6th leading cause worldwide. It is estimated that by 2020, 
it would become the 3rd leading cause of death in the US and worldwide. Affecting 
24 million people in the US, up to half of them undiagnosed, it accounts for 13.76 
million ofﬁ  ce visits, 1.5 million emergency room visits and 726,000 hospitalizations 
annually, at an estimated direct cost of $18 billion (NHLBI 2003).
COPD is a chronic disease and is mostly managed on an outpatient basis. Part of 
the natural history of this disease is intermittent acute episodes of increased respira-
tory symptoms and worse pulmonary function that may be accompanied by fever 
and other constitutional symptoms, which are characterized as acute exacerbations. 
These exacerbations are a major driver for ofﬁ  ce visits, hospitalizations and therefore 
cost of care in COPD. In advanced disease, they are also the most frequent cause of 
death in this disease (Burrows and Earle 1969; Calverley et al 2007). The frequency 
of exacerbations varies widely between patients, but is generally correlated with the 
severity and duration of underlying COPD.
Besides mortality, exacerbations of COPD are associated with important decrements 
in health-related quality of life (Seemungal et al 1998; Spencer et al 2001). Though 
the acute symptoms tend to subside over the course of 2–3 weeks, quality of life takes 
several months to recover. Furthermore, this recovery is delayed if exacerbations International Journal of COPD 2008:3(1) 32
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recur during this recover period (Spencer and Jones 2003). 
Contrary to previous studies, recent data has shown that the 
frequency of exacerbations is associated with accelerated 
long term decline in lung function as measured by the forced 
expiratory volume in 1 second (FEV1). This has been shown 
in mild disease, in the Lung Health Study, where every lower 
respiratory tract illness was associated with an additional loss 
of 7 ml of FEV1 (Kanner et al 2001). Patients with moderate 
to severe COPD who experience more frequent exacerbations 
also experience a decline in FEV1 of 40 ml/yr in contrast 
to a decline of 32 ml/year among patients with infrequent 
exacerbations (Donaldson et al 2002).
It is now clear that exacerbations are a major contributor 
to the morbidity, costs and mortality associated with COPD. 
Substantial progress has also been made in understanding 
their etiology and pathogenesis. In contrast, clinical studies 
of adequate design and quality that can help us determine 
the optimal management approach to exacerbations are 
still relatively few. Among the therapeutic options for the 
treatment of acute exacerbations are antibiotics. Though 
widely used for the treatment of exacerbations, their use 
is still debated and whether antibiotic choice is important 
is controversial (Hirschmann 2000; Murphy et al 2000). 
The optimal approach to antibiotic treatment of exacerba-
tions relies upon an accurate diagnosis, including judicious 
application of diagnostic tests. This needs to be followed by 
determining the severity of an exacerbation, the probability 
that it is bacterial and whether antibiotics are indicated. Once 
the decision is made that antibiotics are indeed indicated, 
then a risk stratiﬁ  cation approach allows us to choose an 
appropriate antibiotic.
Diagnosis of acute exacerbation
Accurate diagnosis relies on clear deﬁ  nitions that are uni-
versally agreed upon and include objective measurements. 
Unfortunately, this is not the situation with acute exacerba-
tions of COPD, with an imprecise and variable deﬁ  nition 
and the absence of objective measures (Rodriguez-Roisin 
2000). There are two widely used deﬁ  nitions of exacerba-
tion. The Anthonisen deﬁ  nition is based on the presence 
of one or more of three cardinal symptoms, including an 
increase or new onset of dyspnea, sputum production and 
sputum purulence (Anthonisen et al 1987). In case only one 
cardinal symptom is present, then one or more supporting 
symptoms or signs are required to make the diagnosis, includ-
ing an upper respiratory tract infection in the past ﬁ  ve days, 
wheezing, cough, fever without an obvious source or a 20% 
increase in the respiratory rate or heart rate above baseline. 
Though simple and clinically useful, this deﬁ  nition is narrow 
in its scope and several important symptoms of exacerbation 
such as chest congestion, chest tightness, fatigue and sleep 
disturbance are not included.
A wider deﬁ  nition from a consensus panel deﬁ  nes an 
exacerbation as an acute sustained worsening of the patients’ 
condition from stable state, beyond day to day variability and 
which requires additional treatment (Rodriguez-Roisin 2000). 
This deﬁ  nition though more inclusive, is not speciﬁ  c with 
regards to the nature and duration of symptoms. Also missing 
in both deﬁ  nitions is the clinical exclusion of entities that could 
present in a similar manner, such as pneumonia, congestive 
heart failure, upper respiratory infection, noncompliance with 
medications etc. Older research in this ﬁ  eld did not exclude 
these entities from the deﬁ  nition, confounding both the research 
ﬁ  ndings and clinical approach to exacerbations. These clinical 
entities have distinct etiology, pathogenesis and treatment, 
and therefore should be in the differential diagnosis of an 
exacerbation rather than be included under the deﬁ  nition.
In our clinical studies, we suspect an exacerbation when a 
patient with COPD reports a minor increase (or new onset) of 
two or a major increase (or new onset) of one of the following 
respiratory symptoms: dyspnea, cough, sputum production, 
sputum tenacity, or sputum purulence (Sethi et al 2002). The 
increase in symptoms should be of at least 24 hours duration 
and should be of greater intensity than their normal day to day 
variability. Other deﬁ  nitions have required symptoms to be 
of at least 48 hrs and even 72 hrs in duration. Furthermore, 
as described above, clinical evaluation should exclude other 
clinical entities that could present in a similar manner.
The severity of an exacerbation is a complicated concept, 
because it is constituted by at least two factors, the severity 
of the underlying COPD and the acute change induced by 
the exacerbation itself. Therefore, a patient who has got very 
severe underlying COPD may have signiﬁ  cant clinical con-
sequences from a relatively small change from his baseline 
state, while a patient with mild COPD may be able to tolerate 
a much larger change in his symptoms and lung function.
Different notions of exacerbation severity have been 
used. Ideally, changes in lung function should be used to 
deﬁ  ne severity of exacerbations. However, lung function 
is difﬁ  cult to measure during exacerbations, and often the 
change with an exacerbation is of the same magnitude as day 
to day variability in these measurements. Severity has been 
also measured by site of care, with hospitalized exacerba-
tions regarded as severe, outpatient exacerbations regarded as 
moderate and self medicated exacerbations as mild (GOLD 
2007). This classiﬁ  cation is prone to error as the site of care International Journal of COPD 2008:3(1) 33
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is dependent on differences among countries and health care 
systems as to the threshold for admission, patient and physi-
cian preferences etc. Another suggested measure of severity 
of exacerbations is the intensity of treatment recommended, 
with treatment with bronchodilators only indicating mild 
exacerbations, while treatment with antibiotics and steroids in 
addition to bronchodilators regarded as indicating moderate 
or severe exacerbations. Again, this approach is beset with 
problems of preferences and practice approach.
One widely used determination of severity is known as the 
Anthonisen classiﬁ  cation (Anthonisen et al 1987). This clas-
siﬁ  cation relies on the number of cardinal symptoms and the 
presence of some supporting symptoms as shown in Table 1. 
Interestingly, this classiﬁ  cation was not designed to be a clas-
siﬁ  cation of severity of exacerbations, but has become so over 
time. This determination of severity is relatively simple and 
does correlate with beneﬁ  t with antibiotics, with such beneﬁ  t 
seen only in Type 1 and 2 exacerbations. However, there are 
limitations to the Anthonisen severity classiﬁ  cation. It has 
not been validated against objective measures of severity. 
The association with beneﬁ  t with antibiotics has not been 
reproduced in other studies. Another limitation is the lack 
of gradation of severity within each symptom, such that an 
exacerbation with mild dyspnea and mild increase in sputum 
would be regarded as the same severity in this classiﬁ  cation 
as one with a marked increase in both symptoms.
It is evident that we need a better deﬁ  nition and objective 
measures of severity of exacerbations. Biomarkers represent 
such an objective measure and potentially could either 
deﬁ  ne an exacerbation, determine its etiology or determine 
its severity. In a recent study by Hurst et al of 36 plasma 
biomarkers in 90 patients with exacerbations, none of 
them alone or in combination were adequate to deﬁ  ne an 
exacerbation (Hurst et al 2006). In another study of multiple 
serum biomarkers in 20 hospitalized patients with exacerbation, 
reduction in interleukin-6 (IL-6) and interleukin-8 (IL-8) 
correlated with decrease in dyspnea during recovery from 
exacerbation, while decreases in IL-6 and tumor necrosis factor 
(TNFα) were proportional to recovery in FEV1 (Pinto-Plata 
et al 2007). Sputum free neutrophil elastase activity has been 
shown to correlate with clinical severity of an exacerbation 
as assessed by a clinical score based on symptoms and signs 
(Sethi et al 2000). Development of patient reported outcomes 
and biomarkers should provide us with a better deﬁ  nition and 
objective measures of severity of exacerbations in the future.
Pathogenesis of exacerbations
The emerging concept that an increase in airway inﬂ  amma-
tion from the baseline level characteristic of COPD is cen-
tral to the pathogenesis of acute exacerbations is supported 
by several recent studies (White et al 2003; Sethi 2004a). 
Measurement of airway inﬂ  ammation in induced or expec-
torated sputum, bronchoalveolar lavage or bronchial biopsy 
has revealed that increased airway inﬂ  ammation is indeed 
present in acute exacerbation and resolves with treatment. 
Both neutrophilic and eosinophilic inﬂ  ammation has been 
described, with the former associated with a bacterial etiology 
and the latter with viral infection. Any stimulus that acutely 
increases airway inﬂ  ammation could lead to increased bron-
chial tone, edema in the bronchial wall and mucus production. 
In an already diseased lung, these processes could worsen 
ventilation-perfusion mismatch and expiratory ﬂ  ow limita-
tion. Corresponding clinical manifestations are dyspnea, 
cough, increased sputum production, tenacity and purulence 
along with worsening gas exchange, which are the cardinal 
manifestations of an exacerbation.
Table 1 Anthonisen classiﬁ  cation of COPD exacerbations based on cardinal symptoms. Based on data from Anthonisen and collea-
gues (1987)
Severity of   Type of   Characteristics
exacerbation exacerbation 
Severe  Type 1  Increased dyspnea, sputum volume and sputum purulence
  
Moderate  Type 2  Any 2 of the above 3 cardinal symptoms
Mild  Type 3  Any 1 of the above 3 cardinal symptoms and
    1 or more of the following minor symptoms or signs
  -  Cough
  -  Wheezing
    - Fever without an obvious source
    - Upper respiratory tract infection in the past 5 days
    - Respiratory rate increase 20% over baseline
    - Heart rate increase 20% over baselineInternational Journal of COPD 2008:3(1) 34
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Increases in plasma ﬁ  brinogen, interleukin 6 (IL-6) and 
c-reactive protein (CRP), consistent with a heightened state of 
systemic inﬂ  ammation have been described during exacerba-
tions (Dev et al 1998; Wedzicha et al 2000). These and other 
mediators likely cause the systemic manifestations of exacer-
bations, including fatigue and in some instances fever.
A variety of noninfectious and infectious stimuli can 
induce an acute increase in airway inﬂ  ammation in COPD, 
thereby causing the manifestations of exacerbation. Epide-
miological studies have demonstrated increased respiratory 
symptoms and respiratory mortality among patients with 
COPD during periods of increased air pollution (Sunyer 
et al 1993; Garcia-Aymerich et al 2000; Sunyer et al 2000). 
Indeed, environmental pollutants, both particulate matter, 
such as PM-10, and nonparticulate gases, such as ozone, 
nitrogen dioxide, sulfur dioxide, are capable of inducing 
inﬂ  ammation in vitro and in vivo (Devalia et al 1994; Ohtoshi 
et al 1998; Rudell et al 1999). Infectious agents, including 
bacteria, viruses and atypical pathogens are implicated as 
causes of up to 80% of acute exacerbations, and are discussed 
in greater detail below (Sethi 2000).
Microbial pathogens in COPD 
exacerbations
The list of potential pathogens in COPD exacerbations includes 
typical respiratory bacterial pathogens, respiratory viruses 
and atypical bacteria (Table 2). Among the typical bacteria, 
nontypeable Haemophilus inﬂ  uenzae (NTHI) is the most com-
mon and its role in COPD is the best understood (Eldika and 
Sethi 2006). Among the viruses, Rhinovirus and Respiratory 
Syncytial Virus (RSV) has received considerable attention in 
recent years (Seemungal et al 2001; Falsey et al 2005).
Certain shared characteristics of these pathogens pro-
vide clues to their predilection for causing infections in 
COPD. NTHI, Streptococcus pneumoniae, and Moraxella 
catarrhalis are the predominant bacterial causes of two other 
common respiratory mucosal infections, acute otitis media 
in children and acute sinusitis in children and adults. These 
mucosal infections have been related to anatomical abnor-
malities with impaired drainage of secretions, antecedent 
viral infections and defects in innate and adaptive immunity. 
All these predisposing factors likely exist in COPD. These 
three pathogens are all exclusively human pathogens that 
are transmitted among individuals. In healthy hosts, their 
presence is conﬁ  ned to the upper airway and does not cause 
any clinical manifestations. It is likely that acquisition of 
these pathogens in a patient with COPD, because of com-
promised lung defense, allows establishment of infection 
in the lower respiratory tract, with or without overt clinical 
manifestations.
Respiratory viruses implicated in COPD are able to cause 
acute tracheo-bronchial infections in healthy hosts, clinically 
Table 2 Microbial pathogens in exacerbations of COPD
Pathogen class  Proportion of exacerbations  Speciﬁ  c species  Proportion of class of pathogens
Bacteria 40%–50%  Nontypeable Haemophilus  30%–50%
   inﬂ  uenzae  
   Streptococcus pneumoniae  15%–20%
   Moraxella catarrhalis  15%–20%
   Pseudomonas spp. and   Isolated in very severe COPD, 
   Enterobacteriaceae   concomitant bronchiectasis, 
     recurrent exacerbations 
   Haemophilus   Isolated frequently, pathogenic 
   parainﬂ  uenzae  signiﬁ  cance undeﬁ  ned
   Haemophilus hemolyticus  Isolated frequently, pathogenic 
     signiﬁ  cance undeﬁ  ned
   Staphylococcus aureus  Isolated infrequently, pathogenic 
     signiﬁ  cance undeﬁ  ned
Viruses 30%–40%  Rhinovirus 40%–50%
   Parainﬂ  uenza  10%–20%
   Inﬂ  uenza   10%–20%
   RSV  10%–20%
   Coronavirus  10%–20%
   Adenovirus  5%–10%
Atypical   5%–10%  Chlamydia pneumoniae 90%–95%
bacteria   Mycoplasma pneumoniae  5%–10%International Journal of COPD 2008:3(1) 35
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referred to as acute bronchitis. In the setting of COPD, with 
diminished respiratory reserve, this acute bronchitis has more 
profound manifestations and serious clinical consequences.
Pathogenesis of infectious 
exacerbations
Our understanding of acute exacerbation pathogenesis, espe-
cially in relation to bacterial infection, has seen signiﬁ  cant 
progress over the last few years. Both host and pathogen fac-
tors are involved in development of acute bacterial exacerba-
tions (Figure 1). Acquisition of strains of bacterial pathogens 
that are new to the host from the environment appears to be 
the primary event that puts the patient with COPD at risk 
for an exacerbation (Sethi et al 2002). Variations among 
strains of a species in the surface antigenic structure, as is 
seen with NTHI, S pneumoniae and M catarrhalis allow 
these newly acquired strains to escape the pre-existing host 
immune response that had developed following prior expo-
sure to other strains of the same species of bacteria. These 
strains can therefore proliferate in the lower airways and 
induce acute inﬂ  ammation in the airways. The virulence 
of the strain and as yet unidentiﬁ  ed host factors may deter-
mine if the acute inﬂ  ammatory response to the pathogen 
reaches the threshold to cause symptoms that present as an 
exacerbation (Chin et al 2005). In many instances, the adap-
tive immune response results in development of mucosal 
and systemic antibodies to the pathogen (Sethi et al 2004; 
Murphy et al 2005). This immune response, in combination 
with appropriate antibiotics, is able to eliminate or control 
proliferation of the infecting bacteria. However, because of 
antigenic variability among strains of these bacterial species, 
the antibodies that develop to the infecting strain are usually 
strain-speciﬁ  c, and do not provide protection to the host 
from other antigenically distinct strains of the same species. 
This allows the process of recurrent bacterial infection and 
exacerbations in these patients.
The pathogenesis of acute viral exacerbations is less well 
understood. However, it appears to be similar to bacterial 
infections. A common cause of exacerbations, the rhinovirus, 
demonstrates considerable antigenic variation among its 
Figure 1 Proposed model of bacterial exacerbation pathogenesis in COPD. Copyright © 2006. Reproduced with permission from Veeramachaneni SB, Sethi S. 2006. Pathogenesis 
of bacterial exacerbations of COPD.  J Chronic Obstructive Pul Dis, 3:109–15.
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more than 100 serotypes, allowing for recurrent infections. 
The inﬂ  uenza virus demonstrates drift in the antigenic make-
up of its major surface proteins, thereby leading to recurrent 
infections. In vitro, viruses can damage airway epithelium, 
stimulate muscarinic receptors, and induce eosinophilic 
inﬂ  ux by stimulating the secretion of RANTES (Johnston 
et al 1998). These pro-inﬂ  ammatory actions could poten-
tially induce the pathophysiological manifestations that 
characterize acute exacerbation when a viral agent infects 
the lower airway of a patient with COPD. The pathogenesis 
of exacerbations with atypical bacterial infection is poorly 
understood.
Goals of treatment of exacerbations
Traditionally, the aims of treatment of an exacerbation are 
the recovery to baseline clinical status and the prevention 
of complications. Though these goals are undoubtedly 
important, several new observations question the adequacy 
of these goals. These include our new understanding of the 
importance of exacerbations in the course of COPD, the role 
of infection in exacerbations, the high rates of relapse with 
an adequate initial clinical response, and the role played by 
chronic infection in the pathogenesis of COPD. To draw 
an analogy, conﬁ  ning our goal in the treatment of COPD 
exacerbations to short term resolution of symptoms would 
be the equivalent of treating acute myocardial infarction 
with the only aim being resolution of chest pain. Several 
other important goals of treatment, both clinical and biologi-
cal, should be considered (Table 3). For instance, clinical 
success in the treatment of exacerbations has been deﬁ  ned 
as resolution of symptoms to baseline or improvement of 
symptoms to a degree that no further treatment is required 
in the opinion of the treating physician. If symptoms do 
indeed correlate with exaggerated airway and systemic 
inﬂ  ammation, then acceptance of clinical improvement rather 
than clinical resolution has important implications. Clinical 
improvement may reﬂ  ect inadequate treatment, permitting 
the inﬂ  ammatory process that underlies the exacerbation 
to persist for prolonged periods of time (White et al 2003). 
Therefore, clinical resolution of symptoms to baseline may 
actually represent the optimal outcome.
Other important clinical goals of treatment include delay-
ing the next exacerbation, prevention of early relapse and 
more rapid resolution of symptoms (Anzueto et al 1999; 
Miravitlles et al 2001; Aaron et al 2003). Lengthening the 
inter-exacerbation interval and prevention of early relapse are 
being increasingly recognized as important clinical goals of 
treatment, because they ultimately translate to a decrease in 
the frequency of exacerbations, which is now a major focus 
of COPD treatment. Though most patients and physicians 
would accept faster recovery to baseline as a desirable goal 
of treatment, acceptance of this goal has been hampered by 
lack of well validated instruments to reliably measure the 
rate of resolution of exacerbations.
Nonclinical goals of treatment are either still in their 
infancy or, in the case of bacteriologic eradication, only 
used in clinical studies to satisfy regulatory requirements 
for approval of new antibiotics. If exacerbations are inﬂ  am-
matory events, it would be logical to have resolution of 
inﬂ  ammation to baseline as an important goal of treatment. 
Similarly, exacerbations are in many instances induced by 
infection, therefore eradication of the offending infectious 
pathogen should be a goal of treatment. Practical application 
of these biological goals of treatment of exacerbations awaits 
the development of simple, rapid and reliable measurements 
of inﬂ  ammation and infection.
Most exacerbations require a multi-pronged approach 
that utilizes several therapeutic modalities simultaneously, 
Table 3 Proposed goals of treatment of COPD exacerbation
Goals Comments
Clinical
Clinical resolution to baseline  Needs baseline assessment prior to exacerbation onset for comparison
Prevention of relapse  Relapse within 30 days is quite frequent
Increasing exacerbation-free interval  Needs long term follow up after treatment
Faster resolution of symptoms  Needs validated symptom assessment tools
Preservation of health-related quality of life  Sustained decrements seen after exacerbations
Biological
Bacterial eradication  Often presumed in usual antibiotic comparison studies
Resolution of airway inﬂ  ammation  Shown to be incomplete if bacteria persist
Resolution of systemic inﬂ  ammation  Persistence of systemic inﬂ  ammation predicts early relapse
Restoration of lung function to baseline  Incomplete recovery is seen in signiﬁ  cant proportion
Preservation of lung function  Needs long term studiesInternational Journal of COPD 2008:3(1) 37
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either to relieve symptoms, to treat the underlying cause or 
provide support till recovery occurs (Sethi 2002; GOLD 
2007). These therapies include bronchodilators, corticoste-
roids, antimicrobials, mucolytics, and expectorants and, in the 
more severe cases, oxygen supplementation and mechanical 
ventilation for acute respiratory failure. The subsequent dis-
cussion will focus on the role of antibiotics in the treatment 
of acute exacerbation.
Antibiotics in the treatment 
of exacerbations
The role and choice of antibiotics in the treatment of exac-
erbations has been a matter of controversy. Recommenda-
tions for antibiotic use among published guidelines are often 
inconsistent, and at times vague (Bach et al 2001; Balter et al 
2003; Celli and MacNee 2004; GOLD 2007). The paucity of 
well-designed, large randomized controlled trials in this ﬁ  eld 
upon which to base solid recommendations has undoubtedly 
contributed to the state of affairs (Sethi 2004b). Recently, 
a few well designed placebo controlled and antibiotic com-
parison trials have been reported. In addition, epidemiologic 
studies have consistently identiﬁ  ed certain ‘risk factors’, the 
presence of which in a patient with an acute exacerbation is 
predictive for failure of treatment or early relapse. There is 
increasing realization that with the heterogeneity of COPD 
and of exacerbations, using the same antibiotic in all episodes 
may not provide optimal outcome. It is likely that a propor-
tion of treatment failures in exacerbations are related to 
ineffective antibiotic treatment. Therefore, patients ‘at risk’ 
for poor outcome are the logical candidates for aggressive 
initial antibiotic treatment, with the expectation that such an 
approach would improve overall outcomes of exacerbation. 
This ‘risk stratiﬁ  cation’ approach has also been advocated for 
other community-acquired infections such as pneumonia and 
acute sinusitis (Mandell et al 2003; Sinus and Allergy Health 
2004). Though improved outcomes with risk stratiﬁ  cation 
has not yet been demonstrated in prospective controlled tri-
als, such an approach takes into account concerns of disease 
heterogeneity, antibiotic resistance and judicious antibiotic 
use in exacerbations.
Placebo-controlled antibiotic trials
In contrast to the magnitude of the problem of exacerbations 
of COPD, resulting in signiﬁ  cant antibiotic consumption, 
there are only a handful of placebo-controlled trials in this 
disease. Two meta-analyses of placebo-controlled trials in 
exacerbations have been published. In the ﬁ  rst such analysis 
published in 1995, only nine trials met quality criteria and 
a small but signiﬁ  cant beneﬁ  cial effect of antibiotics over 
placebo in acute exacerbation was demonstrated (Saint et al 
1995). In the second analysis, 11 trials were included, and a 
much larger beneﬁ  cial effect on mortality and prevention of 
clinical failure was demonstrated, especially in moderate to 
severe exacerbations (Ram et al 2006). The numbers needed 
to treat in severe exacerbations in hospitalized patients to 
prevent one death was only three patients and the number 
needed to treat for the prevention of one clinical failure was 
six patients. Diarrhea was the most frequently related adverse 
effect, with one episode per seven patients treated. Antibiotic 
treatment was beneﬁ  cial in resolving sputum purulence; 
however beneﬁ  ts on lung function and gas exchange were 
not observed.
The different results between the two meta-analyses can 
be explained in large part by the addition in the later analy-
sis of a study performed in Tunisia that was published in 
2003. In this study, 93 patients with exacerbations of severe 
underlying COPD requiring ventilator support in an inten-
sive care unit were randomly assigned to receive oﬂ  oxacin 
or placebo in a double blind manner (Nouira et al 2001). No 
systemic corticosteroids were administered. Potential respira-
tory bacterial pathogens were isolated in tracheo-bronchial 
aspirates in 61% of patients. Oﬂ  oxacin resulted in a dramatic 
beneﬁ  t when compared to placebo, reducing mortality and 
the need for additional antibiotics by 17.5-fold and 28.4-fold, 
respectively (Table 4).
Another interesting study, though not included in either 
meta-analysis, was published in Italian by Allegra and col-
leagues (1991) with an additional analysis later published in 
English. In this trial, amoxicillin/clavunate was compared 
with placebo in 414 exacerbations in 369 patients with 
varying severity of underlying COPD (Allegra et al 2001). 
A unique feature of this study was the measurement of pri-
mary outcome at 5 days, instead of the traditional 2–3 weeks. 
Clinical success (including resolution and improvement) 
Table 4 Results of a recent placebo controlled trial in exacerba-
tions of COPD requiring intensive care unit admission. Based on 
data from Nouira and colleagues (2001)
Outcome Oﬂ  oxacin  Placebo  Risk reduction  p value
 (n  = 47)  (n = 46)   
Hospital mortality  2 (4%)  10 (22%)  17.5   0.01
      (4.3 to 30.7) 
Additional   3 (6%)  16 (35%)  28.4   0.0006
antibiotics      (12.9 to 43.9) 
Combined primary   5 (11%)  26 (57%)  45.9   0.0001
outcomes     (29.1  to  62.7) International Journal of COPD 2008:3(1) 38
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was signiﬁ  cantly better with the antibiotic, seen in 86.4% of 
patients, compared with 50.6% in the placebo arm. Greater 
beneﬁ  t with antibiotics as compared to placebo was seen 
with increasing severity of underlying COPD.
Results of the meta-analyses and this study, along with 
those of the previous classic large placebo-controlled trial 
conducted by Anthonisen and colleagues show that antibi-
otics are beneﬁ  cial in the treatment of moderate to severe 
exacerbations (Anthonisen et al 1987; Allegra et al 2001; 
Nouira et al 2001; Ram et al 2006). Furthermore, the beneﬁ  t 
with antibiotics is more marked early in the course of the 
exacerbation, suggesting that antibiotics hasten resolution 
of symptoms (Allegra et al 2001; Miravitlles et al 2001). 
However, there are still important unresolved questions 
regarding the role of antibiotics in exacerbations. The beneﬁ  t 
of antibiotics in mild exacerbations is unproven and warrants 
a placebo controlled trial. Whether antibiotics are of beneﬁ  t 
in the treatment of exacerbations when a short course of sys-
temic corticosteroids are co-administered has still not been 
studied in a large well designed trial. One would suspect that 
there would be additive beneﬁ  ts when both treatments are 
used over either treatment alone (Wood-Baker et al 2005; 
Ram et al 2006).
Antibiotic comparison trials
Though one can be quite conﬁ  dent that antibiotics are use-
ful in moderate to severe exacerbations of COPD, there is 
considerable discussion as to antibiotic choice, especially 
for initial empiric therapy (Bach et al 2001; Balter et al 
2003; Celli and MacNee 2004; Sethi and Murphy 2004; 
GOLD 2007). As most exacerbations nowadays are treated 
without obtaining sputum bacteriology, this initial empiric 
choice often becomes the only choice made for antibiotic 
use in exacerbations. Results of antibiotic comparison trials 
should guide the recommendations for appropriate empiric 
antibiotics in exacerbations. However, though a large number 
of such trials have been conducted, in the vast majority, anti-
biotic choice does not appear to affect the clinical outcome. 
Differences in bacteriological eradication rates are seen, 
with an apparent dissociation between clinical and bacterio-
logical outcomes (Obaji and Sethi 2001). This is contrary to 
expectations that antibiotics with better in vitro and in vivo 
antimicrobial efﬁ  cacy and better pharmacodynamic and 
pharmacokinetic characteristics should show superiority in 
clinical outcomes. This paradox is likely related to several 
short-comings in design of these trials (Table 5) (Sethi 
2004b). Many of these deﬁ  ciencies are explained by the fact 
that these trials are performed for regulatory approval of the 
drugs, therefore are designed for demonstrating noninferior-
ity rather than differences between the two antibiotics.
Two recent antibiotic comparison trials were designed 
to show differences among antibiotics and measured 
some unconventional but clinically relevant end-points. 
The GLOBE (Gemiﬂ  oxacin and Long term Outcome of 
Bronchitis Exacerbations) trial was a prospective, double 
blind, randomized trial that compared a ﬂ  uoroquinolone, 
gemiﬂ  oxacin, with a macrolide, clarithromycin (Wilson et al 
2002). End of therapy and long-term outcome assessments 
were made at the conventional 10–14 day and 28 day time 
intervals. In these assessments, in line with most antibiotic 
comparison trials, there was no statistically significant 
difference in the two arms in the clinical outcome, with 
clinical success rates of 85.4% and 84.6% for gemiﬂ  oxacin 
and clarithromycin respectively. Bacteriological success, 
Table 5 Limitations of published placebo-controlled antibiotic trials in acute exacerbations of COPD. Copyright © 2004. Reproduced 
with permission from Sethi S. 2004a. Bacteria in exacerbations of chronic obstructive pulmonary disease. Phenomenon or 
epiphenomenon? Proc Am Thorac Soc, 1:109–14
Limitation of study design  Potential consequences
Small number of subjects  Type 2 error
Subjects with mild or no underlying COPD included  Diminished overall perceived efﬁ  cacy of antibiotics
Nonbacterial exacerbations included  Type 2 error
End-points compared at 3 weeks after onset  - Spontaneous resolution mitigates differences between arms 
  - Clinically irrelevant as most decisions about 
  antibiotic efﬁ  cacy are made earlier
Speed of resolution not measured  Clinically relevant end-point not assessed
Lack of long-term follow up  Time to next exacerbation not assessed
Antibiotic resistance to agents with limited in vitro  Diminished overall perceived efﬁ  cacy of 
antimicrobial efﬁ  cacy   antibiotics
Poor penetration of antibiotics used in to   Diminished overall perceived efﬁ  cacy of 
respiratory tissues  antibiotics
Concurrent therapy not controlled  Undetected bias in use of concurrent therapyInternational Journal of COPD 2008:3(1) 39
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measured as eradication and presumed eradication, was 
signiﬁ  cantly higher with gemiﬂ  oxacin (86.7%) compared 
to clarithromycin (73.1%).
Patients who had a successful clinical outcome at 28 
days were then offered enrollment in a follow up period for 
a total of 26 weeks of observation. In this time period, the 
primary outcomes were the rate of repeat exacerbations, 
hospitalizations for respiratory disease and health-related 
quality of life measures. Gemiﬂ  oxacin was associated with 
a signiﬁ  cantly lower rate of repeat exacerbations, with 71% 
of the gemiﬂ  oxacin-treated patients remaining exacerbation 
free at 26 weeks in comparison to 58.5% in the clarithromycin 
arm. The relative risk reduction for recurrence of exacerba-
tion was 30%. The rate of hospitalization for respiratory tract 
illness in the 26 weeks was also lower in the gemiﬂ  oxacin-
treated patients than in the clarithromycin treated patients 
(2.3% vs. 6.3%, p = 0.059) (Wilson et al 2002). Patients 
who had a recurrent exacerbation in the 26 week period had 
a lesser improvement in their health-related quality of life 
when compared to those who remained free of recurrence 
(Spencer and Jones 2003). This trial clearly demonstrates 
the limitation of the conventional medium-term clinical 
outcomes to demonstrate differences among antibiotics in 
exacerbations. If the 26 week follow up period had not been 
instituted, signiﬁ  cant differences in clinically relevant out-
comes of recurrence of exacerbations and respiratory related 
hospitalization would have been missed.
Another recent landmark antibiotic comparison trial is the 
MOSAIC trial. This trial is a large study in which patients 
were randomized to a ﬂ  uoroquinolone, moxiﬂ  oxacin or 
to standard therapy (which could be one of the following: 
amoxicillin, cefuroxime or clarithromycin) (Wilson et al 
2004). This trial had several unique design features which 
relate to observations made in this study. A relatively large 
number of patients were enrolled. In addition, patients were 
enrolled when stable to establish a baseline as a comparison 
to reliably distinguish between clinical improvement and 
resolution following treatment. A substantial proportion of 
the patients enrolled had one or more risk factors that would 
predispose to a poor outcome as discussed below. Patients 
were followed up to 9 months after randomization to provide 
an estimate of recurrence of exacerbation.
Interestingly, in line with usual antibiotic comparison 
trials, moxifloxacin and standard therapy were equiva-
lent (88% vs 83%) when clinical success (resolution and 
improvement) was compared at 7–10 days after the end of 
therapy. However, moxiﬂ  oxacin therapy was associated 
with a superior clinical cure rate (deﬁ  ned as resolution of 
symptoms to baseline, rather than simply improvement) than 
standard therapy (71% vs 63%), as well as with superior 
bacteriologic response (91.5% vs 81%). In addition, when 
other a priori unconventional end-points were examined, 
moxiﬂ  oxacin was associated with fewer requirements for 
additional antibiotic therapy (8% vs 14%) and an extended 
time to the next exacerbation (131 versus 104 days) (Wilson 
et al 2004). A composite end-point of clinical failure, require-
ment of additional antibiotics and recurrence of exacerbation 
demonstrated a clear difference between the two arms in the 
study, with moxiﬂ  oxacin being superior to standard therapy 
for up to 5 months of follow up (Figure 2). Again, if the 
conventional outcome of clinical success would have been 
measured solely in this study, all the other signiﬁ  cant differ-
ences in the two arms would have not been discovered.
Results of the GLOBE and MOSAIC trials demonstrate that 
in vitro microbiologic superiority of the ﬂ  uoroquinolones does 
translate to greater in vivo effectiveness in treating patients 
with acute exacerbation. Differences among antibiotics are 
often not perceptible with the standard regulatory end-point 
of clinical success at 7–14 days after the end of therapy. 
However, differences among antibiotics are perceptible when 
clinically relevant end-points such as speed of resolution, 
clinical cure, need for additional antimicrobials and time to 
next exacerbation are considered (Wilson et al 2002, 2004).
Risk stratiﬁ  cation of patients
Based on the MOSAIC and GLOBE studies results, it would 
be tempting to prescribe ﬂ  uoroquinolones for all moderate to 
severe exacerbations. However, it is clear that such a strategy, 
though likely to be successful in the short-term, would foster 
antimicrobial resistance to these valuable antibiotics in the 
long term. Therefore, it would be judicious to make an effort 
to identify those patients that are most likely to beneﬁ  t from 
these antibiotics.
Several studies have now demonstrated that certain patient 
characteristics that antedate the onset of the exacerbation impact 
the outcome of the exacerbation (Ball et al 1995; Adams et al 
2000; Dewan et al 2000; Miravitlles et al 2001; Groenewegen 
et al 2003; Wilson et al 2006). Interestingly, several of these 
characteristics are relevant to outcome in more than one study. 
These risk factors for poor outcome should be considered in 
the decision regarding choice of antibiotics when treating 
exacerbations. Theoretically, patients at greater risk for poor 
outcome would have the greatest beneﬁ  t from early aggressive 
antibiotic therapy, such as with the ﬂ  uoroquinolones. These 
are the patients in whom the consequences of treatment with 
an antibiotic ineffective against the pathogen causing the International Journal of COPD 2008:3(1) 40
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exacerbation are likely to be signiﬁ  cant, with clinical failures, 
hospitalizations and early recurrences likely.
Among the risk factors for poor outcome identiﬁ  ed in 
various studies are increasing age, severity of underlying 
airway obstruction, presence of co-morbid illnesses (especially 
cardiac disease), a history of recurrent exacerbations, use of 
home oxygen, use of chronic steroids, hypercapnia and acute 
bronchodilator use (Ball et al 1995; Adams et al 2000; Dewan 
et al 2000; Miravitlles et al 2001; Groenewegen et al 2003; 
Wilson et al 2006). Some of these risk factors are likely to 
be highly correlated to each other, such as home oxygen use, 
hypercapnia and chronic steroid use likely reﬂ  ect increasing 
severity of underlying COPD. Acute bronchodilator use 
could be related to the severity of underlying COPD or 
reﬂ  ect the wheezy phenotype of exacerbation that may be less 
responsive to antibiotic treatment. Many of the risk factors 
discussed above are continuous in severity, however, certain 
thresholds have been deﬁ  ned in studies that are clinically 
useful and predictive of poor outcome. These include an age 
of more than 65 yrs, FEV1 less than 50%, and more than 3 
exacerbations in the previous 12 months.
In addition to the risk factors described above, experience 
in other respiratory infections tells us that recent antibiotic 
use, within the past 3 months, places the patient in a high risk 
group for harboring antibiotic resistant pathogens and there-
fore having a poor outcome. This has been best described 
for S pneumoniae among patients with community acquired 
pneumococcal pneumonia and recently also described for 
this pathogen among patients with COPD ( Vanderkooi et al 
2005; Sethi et al 2006). Whether such selection for antibiotic 
resistant strains occurs among NTHI and M catarrhalis after 
antibiotic exposure is not known.
Risk stratiﬁ  cation approach 
to antibiotic therapy in acute 
exacerbation
A risk stratiﬁ  cation approach has been advocated by several 
experts for the initial empiric antibiotic treatment of acute 
exacerbation based on the risk factors discussed above and 
the in vitro and in vivo efﬁ  cacy of antibiotics. Our current 
treatment algorithm which is very similar to what others have 
advocated is shown (Figure 3) (Balter et al 2003; Sethi and 
Murphy 2004; GOLD 2007). The initial step in the algorithm 
is the determination of the severity of the exacerbation. Based 
on the discussion above, we use the Anthonisen criteria of 
single cardinal symptom exacerbations deﬁ  ned as mild, while 
the presence of 2 or all 3 of the cardinal symptoms deﬁ  nes 
moderate and severe exacerbations.
Mild exacerbations are managed with symptomatic 
treatment and antibiotics are not prescribed unless the symptoms 
progress. In moderate to severe exacerbations, the important 
step is the differentiation of ‘uncomplicated’ (simple) patients 
Figure 2 Life-table analysis of time to the ﬁ  rst composite event (treatment failure, and/or new exacerbation and/or any further antibiotic treatment) stratiﬁ  ed according to the 
time of the last exacerbation prior to randomization. Copyright © 2004. Reprinted with permission from Wilson R,   Allegra L, et al 2004. Short-term and long-term outcomes 
of moxiﬂ  oxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest, 125:953–64.International Journal of COPD 2008:3(1) 41
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from the ‘complicated’ patients. Uncomplicated patients do 
not have any of the risk factors for poor outcome. Complicated 
patients have one or more of the following risk factors for poor 
outcome: Age 65yrs, FEV150%, co-morbid cardiac disease, 
3 or more exacerbations in the previous 12 months (Balter 
et al 2003; Sethi and Murphy 2004; GOLD 2007). Antibiotic 
choices for patients with uncomplicated COPD include an 
advanced macrolide (azithromycin, clarithromycin), a ketolide 
(telithromycin), a cephalosporin (cefuroxime, cefpodoxime 
or cefdinir), doxycycline or trimethoprim/sulfamethoxazole. 
Amoxicillin is not an appropriate choice with the considerable 
incidence of β-lactamase production among NTHI and
M catarrhalis, two of the major pathogens of exacerbation. In 
complicated patients, antibiotic choices include a respiratory 
ﬂ  uoroquinolone (moxiﬂ  oxacin, gemiﬂ  oxacin, levoﬂ  oxacin) 
or amoxicillin/clavulanate.
In choosing an antibiotic, other considerations are also 
important. In all such patients, exposure to antibiotics within 
the past 3 months should be elucidated. Exposure to antibiotic 
is not conﬁ  ned to those prescribed for respiratory infections, 
but includes antibiotics prescribed for any indication. The 
antibiotic chosen should be from a different class of agents 
from the one prescribed within the past 3 months. For exam-
ple, exposure to a macrolide in the past three months should 
Figure 3 Algorithm for antibiotic treatment of acute exacerbations of COPD.
Exacerbation
Simple COPD
No risk factors 
Age 65yrs
FEV1 50% predicted
3 exacerbations/yr
No cardiac disease
Mild
Only 1 of the 3 cardinal symptoms: 
Increased dyspnea
Increased sputum volume
Increased sputum purulence
Moderate or Severe
At least 
Increased dyspnea
Increased sputum volume
Increased sputum purulence
Complicated COPD
1 or more risk factors
Age 65yrs
FEV1 50% predicted
≥3 exacerbations/yr
Cardiac disease
- Advanced macrolide (azithromycin, 
clarithromycin),
- Cephalosporin (cefuroxime, 
cefpodoxime, cefdinir),
- Ketolide (telithromycin)
- Doxycycline
- Trimethoprim/sulfamethoxazole
* If recent (3 months) antibiotic 
exposure, use alternative class
Worsening clinical status or inadequate response in 72 hrs
Re-evaluate
Consider sputum culture
- No antibiotics
- Increase Bronchodilators
- Symptomatic therapy
- Instruct patient to report additional 
cardinal symptoms
- Fluoroquinolone (moxifloxacin, 
gemifloxacin, levofloxacin),
- Amoxicillin/clavunate
- * If at risk for Pseudomonas
consider ciprofloxacin and obtain 
sputum culture
* If recent (3 months) antibiotic 
exposure, use alternative class
2 of the 3 cardinal symptoms:International Journal of COPD 2008:3(1) 42
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lead to use of a cephalosporin in an uncomplicated patient. 
Similarly, prior use of a ﬂ  uoroquinolone in a complicated 
patient should lead to use of amoxicillin/clavulanate.
There is a sub-group of the complicated patients who 
are at risk for infection by Pseudomonas aeruginosa and 
Enterobacteriaceae or have a documented infection by these 
pathogens (Soler et al 1998). These patients have usually 
very severe underlying COPD (FEV135%), have developed 
bronchiectasis, are hospitalized (often requiring intensive 
care), or have been recently hospitalized or have received 
multiple courses of antibiotics. In such patients, empiric treat-
ment with ciproﬂ  oxacin is appropriate. However, emerged 
resistance among P aeruginosa to the ﬂ  uoroquinolones may 
compromise their efﬁ  cacy. Therefore, in this sub-group of 
patients, a sputum (or tracheobronchial aspirate if intubated) 
culture should be obtained to allow adjustment of antibiotics 
based on the in vitro susceptibility of pathogens isolated. 
However, combination or parenteral antibiotic therapy for 
P aeruginosa in this setting has never been systematically 
examined and is of unproven beneﬁ  t.
Patients should be re-assessed at 48–72 hrs, in which 
time frame clinical improvement should be apparent. In 
patients who fail initial empiric antimicrobial therapy, it 
would be appropriate to re-examine the patient to conﬁ  rm the 
diagnosis, consider sputum studies to ascertain for resistant 
or difﬁ  cult to treat pathogens and treat with an alternative 
agent with better in vitro microbiological efﬁ  cacy.
Alternative approaches to antibiotic 
therapy in acute exacerbation
Purulence of sputum, ie, the amount of yellow and green 
pigmentation in sputum is related to the presence of 
myeloperoxidase, a product of neutrophil degranulation. 
As neutrophil degranulation is associated with bacterial 
infection, purulent sputum at exacerbation has been 
shown to be a marker of bacterial infection, deﬁ  ned by 
quantitative cultures of sputum as well as bronchoscopic 
protected specimen brush specimens (Stockley et al 2000; 
Soler et al 2007). Presence of sputum purulence has been 
advocated as the sole determinant for antibiotic treatment of 
exacerbations. However, its accuracy and reproducibility as 
an indicator of bacterial infection is limited, and is likely to 
be even more so in clinical practice than in research studies 
(Stockley et al 2000; Soler et al 2007). Sputum purulence is 
incorporated in the Anthonisen criteria, and should be used 
in conjunction with other symptoms and other measures of 
risk stratiﬁ  cation in antibiotic treatment of exacerbations 
(Figure 3).
Biomarkers of bacterial infection represent another 
approach to antibiotic use in exacerbations of COPD. The 
best studied biomarker of bacterial infection is serum pro-
calcitonin level. In a recent study in patients hospitalized 
for exacerbations, antibiotic treatment was only prescribed 
if the procalcitonin level was above a certain threshold. The 
investigators showed no difference in outcomes in spite of 
reduction in antibiotic use from 72% to 40% with procalci-
tonin guidance (Stolz et al 2007). Though the ﬁ  ndings of this 
study are very interesting, this approach needs to be validated 
in multi-center trials with varied populations (Martinez and 
Curtis 2007). Furthermore, it needs to tested in outpatients 
with exacerbations, where the majority of exacerbations 
are treated, patients are not as closely supervised and other 
supportive care is less rigorous. Only a minority of patients 
received a ﬂ  uoroquinolones in this study, which should have 
been the antibiotics of choice in these complicated patients, 
as per the risk stratiﬁ  cation discussed above. Therefore, a 
reasonable speculation is that withholding antibiotics that 
may not be effective in the ﬁ  rst place is likely not to have 
much of an impact. In this study, short term goals as well 
as biologic goals of bacterial eradication and inﬂ  ammation 
reduction as discussed above were also not recorded.
Other important considerations in antibiotic prescribing are 
safety and tolerability of the agent, drug interactions and ﬁ  nally 
cost of treatment. Cost of the antibiotic however should not 
be interpreted in isolation. As shown elegantly by Miravittles 
and colleagues (2002) exacerbations for which initial empiric 
treatment fails are ten times as costly as clinical successes 
(Miravitlles et al 2002). In fact, the overall cost of care could 
be reduced by half with only a 33% reduction in clinical failure 
rates. Clinical failure rates are likely to be reduced when antibi-
otic choice is appropriate and logical, as discussed above.
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